Primary Androgen Deprivation Raises Diabetes Risk by 60 Percent

Share this content:
Primary androgen deprivation therapy increases diabetes risk, particularly in men under 70 years of age.
Primary androgen deprivation therapy increases diabetes risk, particularly in men under 70 years of age.

Primary androgen deprivation therapy increases diabetes risk, particularly in men under 70 years of age, according to research published in The Journal of Urology.

Huei-Ting Tsai, Ph.D., from the Georgetown University Medical Center in Washington, D.C., and colleagues analyzed retrospective data from 12,191 men diagnosed with incident localized prostate cancer from 1995 to 2008 (age 35 to 100 years).

The men were without diabetes at diagnosis and did not receive prostatectomy or radiation. Primary androgen deprivation therapy was characterized as occurring within one year of diagnosis.

The researchers found that over a median 4.8 years of follow up, 9.9 percent of patients developed diabetes. The respective incidence rates were 2.5 and 1.6 events per 100 person-years in the primary androgen deprivation therapy and nonprimary androgen deprivation therapy groups.

There was a 1.61-fold increase in diabetes risk with primary androgen deprivation therapy. The number needed to harm was 29. In men ≤70 years, the association was stronger, compared to older men (HR 2.25 versus 1.40; P = 0.008).

RELATED: Identifying Genetic Variations Associated with Risk of Prostate Cancer

"Primary androgen deprivation therapy may increase diabetes risk by 60 percent and should be used with caution when managing localized prostate cancer," the authors write.

"Because of the consistent association between androgen deprivation therapy and greater diabetes risk across disease states, we recommend routine screening and lifestyle interventions to reduce the risk of diabetes in men receiving androgen deprivation therapy."

Reference

  1. Tsai, Huei-Ting, et al. "Risk of Diabetes among Patients Receiving Primary Androgen Deprivation Therapy for Clinically Localized Prostate Cancer." The Journal of Urology. DOI: http://dx.doi.org/10.1016/j.juro.2014.12.027. December 15, 2014.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs